BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TQH3906 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TQH3906\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06754891-52@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:TQH3906: Phase 1 readout est. (NCT06754891)
DESCRIPTION:TQH3906\, phase 1\, Ulcerative Colitis.\nStudy: Clinical Trial 
 of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to
  Severely Active Ulcerative Colitis or Crohn's Disease\nEstimated primary 
 completion: July 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tqh3906#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06754891
URL:https://assetmemo.bio/drug/tqh3906#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07406035-52@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:TQH3906: Phase 2 readout est. (NCT07406035)
DESCRIPTION:TQH3906\, phase 2\, Psoriatic Arthritis.\nStudy: A Clinical Tri
 al of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis\nEst
 imated primary completion: August 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tqh3906#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07406035
URL:https://assetmemo.bio/drug/tqh3906#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07724366-52@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:TQH3906: Phase 3 readout est. (NCT07724366)
DESCRIPTION:TQH3906\, phase 3\, Psoriasis.\nStudy: A Clinical Trial of TQH3
 906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis\nE
 stimated primary completion: September 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tqh3906#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07724366
URL:https://assetmemo.bio/drug/tqh3906#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509892-52@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:TQH3906: Phase 2 readout est. (NCT07509892)
DESCRIPTION:TQH3906\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A Cli
 nical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Syst
 emic Lupus Erythematosus\nEstimated primary completion: November 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tqh3906#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07509892
URL:https://assetmemo.bio/drug/tqh3906#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
